CRVS Stock Risk & Deep Value Analysis
Corvus Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRVS Stock
We analyzed Corvus Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRVS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CRVS Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for CRVS?
- ⚠
Negative or inconclusive results from ongoing/future clinical trials
- ⚠
Failure to secure sufficient funding for Phase 3 trials and commercialization
- ⚠
Increased competitive pressure from new therapies targeting T-cell lymphoma or A2A pathway
- ⚠
Regulatory delays or rejection of approval applications
Unlock CRVS Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Corvus Pharmaceuticals Inc (CRVS) Do?
Market Cap
$534.27M
Sector
Healthcare
Industry
Biotechnology
Employees
31
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Visit Corvus Pharmaceuticals Inc WebsiteIs CRVS Stock Undervalued?
Unlock the full AI analysis for CRVS
Get the complete DVR score, risk analysis, and more
Does CRVS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily built on the intellectual property surrounding its novel compounds and the compelling clinical data (CPI-818). Should CPI-818 receive approval, its efficacy and safety profile would create significant switching costs for physicians and patients, establishing a durable, albeit narrow, competitive advantage in its target indications.
Moat Erosion Risks
- •Development of superior competing therapies by larger pharmaceutical companies
- •Loss of patent protection or IP challenges
- •Clinical trial failures for subsequent pipeline candidates
CRVS Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CRVS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early-May 2026)
- •Initiation of CPI-818 Phase 3 clinical trial in T-cell lymphoma (Q2/Q3 2026)
- •Updated clinical data readout for CPI-006 combination studies (Mid-2026)
Medium-Term (6-18 months)
- •Potential strategic partnership announcement for CPI-818 (ex-US rights, Late 2026/Early 2027)
- •Submission of Breakthrough Therapy designation or accelerated approval pathway discussions for CPI-818 (Late 2026/Early 2027)
- •Initial data from broader CPI-006 solid tumor cohorts (Early 2027)
Long-Term (18+ months)
- •Potential BLA/NDA filing and approval of CPI-818 (2028-2029)
- •Establishment as a market leader in niche oncology segments (T-cell lymphomas)
- •Expansion of pipeline through in-house discovery or M&A to diversify revenue streams
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CRVS?
- ✓
Confirmation of CPI-818 accelerated approval pathway or successful Phase 3 initiation
- ✓
Announcement of a significant partnership or licensing deal for CPI-818
- ✓
Substantial improvement in cash runway through non-dilutive means
- ✓
Further positive data from CPI-006 development
Bull Case Analysis
See what could go right with Premium
Compare CRVS to Similar Stocks
See how Corvus Pharmaceuticals Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRVS (Corvus Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
